DAVID MILLER: Open Payments
NPI 1538140413 · STANFORD, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$838 in 39 payments from 19 companies in 2025. Trend: 2023 $653 · 2024 $790 · 2025 $838
Food & beverage: $818Education: $20
| Company | Payments | Amount |
|---|---|---|
| E.R. Squibb & Sons, L.L.C. | 6 | $139 |
| Merck Sharp & Dohme LLC | 5 | $117 |
| Bayer Healthcare Pharmaceuticals Inc. | 4 | $76 |
| Amgen Inc. | 4 | $66 |
| Novartis Pharmaceuticals Corporation | 3 | $62 |
| PFIZER INC. | 3 | $57 |
| Alnylam Pharmaceuticals Inc. | 1 | $37 |
| AstraZeneca Pharmaceuticals LP | 2 | $36 |
| ABIOMED | 1 | $36 |
| Daiichi Sankyo Inc. | 1 | $29 |
Products named: ELIQUIS, Kerendia, VERQUVO, Repatha, LEQVIO, CAPVAXIVE, VYNDAQEL, AMVUTTRA.
Industry payments across CA — which companies pay providers there.
